Cassava (SAVA) Begins First Efficacy Study on Simufilam in AD Posted byZacks Equity Research October 7, 2021 Leave a comment on Cassava (SAVA) Begins First Efficacy Study on Simufilam in AD Cassava (SAVA) starts a phase III efficacy study evaluating simufilam for treating patients with Alzheimer’s disease.